Newly Approved OTC Eye Drop Could Boost Valeant Turnaround Outlook
Executive Summary
Valeant's Bausch + Lomb subsidiary will have market exclusivity for Lumify, the first OTC brimonidine eye drop. It likely will provide a needed revenue boost as the parent firm navigates a turnaround after incurring more than $30bn debt during the turbulent period under previous management.
You may also be interested in...
Valeant Launches Lumify OTC Eye Drops With Vision Of Better Days As Bausch
Lumify eye drops, the first OTC brimonidine tartrate ophthalmic solution 0.025% in the US, will reach stores in late May. Corporate name change, says CEO Joseph Papa, shows Valeant is "beginning to turn the page away from legacy issues that have been headwinds over the past few years."
Valeant Launches Lumify OTC Eye Drops With Vision Of Better Days As Bausch
Lumify eye drops, the first OTC brimonidine tartrate ophthalmic solution 0.025% in the US, will reach stores in late May. Corporate name change, says CEO Joseph Papa, shows Valeant is "beginning to turn the page away from legacy issues that have been headwinds over the past few years."
Valeant Returns $1bn Female Libido Drug For Free
At first glance, giving back Addyi to the original owners for next to nothing looks like a complete disaster but investors are relieved debt-ridden Valeant has managed to offload another asset.